161 related articles for article (PubMed ID: 25324884)
1. Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility.
Kim HY; Moon C; Kim KS; Oh KW; Oh SI; Kim J; Kim SH
J Clin Neurol; 2014 Oct; 10(4):342-7. PubMed ID: 25324884
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.
Lauria G; Campanella A; Filippini G; Martini A; Penza P; Maggi L; Antozzi C; Ciano C; Beretta P; Caldiroli D; Ghelma F; Ferrara G; Ghezzi P; Mantegazza R
Amyotroph Lateral Scler; 2009; 10(5-6):410-5. PubMed ID: 19922132
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.
Lauria G; Dalla Bella E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Fazio R; Filosto M; Giannini F; Granieri E; La Bella V; Logroscino G; Mandrioli J; Mazzini L; Monsurrò MR; Mora G; Pietrini V; Quatrale R; Rizzi R; Salvi F; Siciliano G; Sorarù G; Volanti P; Tramacere I; Filippini G;
J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):879-86. PubMed ID: 25595151
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
5. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study.
Prabhakar S; Marwaha N; Lal V; Sharma RR; Rajan R; Khandelwal N
Neurol India; 2012; 60(5):465-9. PubMed ID: 23135021
[TBL] [Abstract][Full Text] [Related]
6. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
8. Multipoint incremental motor unit number estimation versus amyotrophic lateral sclerosis functional rating scale and the medical research council sum score as an outcome measure in amyotrophic lateral sclerosis.
Jagtap SA; Kuruvilla A; Govind P; Nair MD; Sarada C; Varma RP
Ann Indian Acad Neurol; 2014 Jul; 17(3):336-9. PubMed ID: 25221407
[TBL] [Abstract][Full Text] [Related]
9. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
10. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
11. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
12. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.
Elia AE; Lalli S; Monsurrò MR; Sagnelli A; Taiello AC; Reggiori B; La Bella V; Tedeschi G; Albanese A
Eur J Neurol; 2016 Jan; 23(1):45-52. PubMed ID: 25664595
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up.
Nabavi SM; Karimi SH; Arab L; Sanjari L; Mardpour S; Azimian V; Jarughi N; Ghaheri A; Hosseini SE; Aghdami N; Vosough M
Cell J; 2021 Dec; 23(7):772-778. PubMed ID: 34979067
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Gotkine M; Caraco Y; Lerner Y; Blotnick S; Wanounou M; Slutsky SG; Chebath J; Kuperstein G; Estrin E; Ben-Hur T; Hasson A; Molakandov K; Sonnenfeld T; Stark Y; Revel A; Revel M; Izrael M
J Transl Med; 2023 Feb; 21(1):122. PubMed ID: 36788520
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R;
Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667
[TBL] [Abstract][Full Text] [Related]
16. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
17. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC
EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270
[TBL] [Abstract][Full Text] [Related]
18. Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort.
Thakore NJ; Lapin BR; Pioro EP;
Muscle Nerve; 2018 Jun; 57(6):937-945. PubMed ID: 29244213
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety of Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis: A Pilot Study.
Shamsaei G; Houshmand F; Ahmadzadeh Deylami A; Valizadeh A; Rafie S; Moradi M
Adv Pharm Bull; 2023 Mar; 13(2):361-367. PubMed ID: 37342380
[No Abstract] [Full Text] [Related]
20. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients.
Park Y; Park J; Kim Y; Baek H; Kim SH
Nutrition; 2015; 31(11-12):1362-7. PubMed ID: 26429656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
